PDE2A Gene

PDE2A Gene

Introduction

Pde2A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

.infobox .infobox-gene { [@pdea]
background-color: #f8f9fa; [@schroder2020]
border: 1px solid #ddd; [^4]
padding: 10px; [@epifantseva2019]
width: 300px; [@reyesirisarri2018]
font-size: 0.9em; [@bollen2017]
} [@domeklopacinska2016]

.infobox .infobox-gene .gene-symbol {
font-weight: bold;
font-size: 1.2em;
color: #2c5282;
}

.infobox .infobox-gene .gene-name {
font-style: italic;
margin-bottom: 10px;
}

.infobox .infobox-gene table {
width: 100%;
border-collapse: collapse;
}

.infobox .infobox-gene td {
padding: 4px;
vertical-align: top;
}

.infobox .infobox-gene td.label {
font-weight: bold;
width: 40%;
color: #555;
}

.infobox .infobox-gene td.value {
width: 60%;
}

.infobox .infobox-gene a {
color: #0066cc;
text-decoration: none;
}

.infobox .infobox-gene a:hover {
text-decoration: underline;
}

PDE2A Gene

Introduction

Pde2A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

.infobox .infobox-gene { [@pdea]
background-color: #f8f9fa; [@schroder2020]
border: 1px solid #ddd; [^4]
padding: 10px; [@epifantseva2019]
width: 300px; [@reyesirisarri2018]
font-size: 0.9em; [@bollen2017]
} [@domeklopacinska2016]

.infobox .infobox-gene .gene-symbol {
font-weight: bold;
font-size: 1.2em;
color: #2c5282;
}

.infobox .infobox-gene .gene-name {
font-style: italic;
margin-bottom: 10px;
}

.infobox .infobox-gene table {
width: 100%;
border-collapse: collapse;
}

.infobox .infobox-gene td {
padding: 4px;
vertical-align: top;
}

.infobox .infobox-gene td.label {
font-weight: bold;
width: 40%;
color: #555;
}

.infobox .infobox-gene td.value {
width: 60%;
}

.infobox .infobox-gene a {
color: #0066cc;
text-decoration: none;
}

.infobox .infobox-gene a:hover {
text-decoration: underline;
}

<div class="infobox">
<div class="infobox-gene">
<div class="gene-symbol">PDE2A</div>
<div class="gene-name">Phosphodiesterase 2A</div>
<table>
<tr><td class="label">Symbol</td><td class="value">PDE2A</td></tr>
<tr><td class="label">Full Name</td><td class="value">Phosphodiesterase 2A</td></tr>
<tr><td class="label">Chromosome</td><td class="value">11q13.4</td></tr>
<tr><td class="label">NCBI Gene</td><td class="value">[5139](https://www.ncbi.nlm.nih.gov/gene/5139)</td></tr>
<tr><td class="label">OMIM</td><td class="value">[602952](https://www.omim.org/entry/602952)</td></tr>
<tr><td class="label">Ensembl</td><td class="value">[ENSG00000186642](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186642)</td></tr>
<tr><td class="label">UniProt</td><td class="value">[O76074](https://www.uniprot.org/uniprotkb/O76074/entry)</td></tr>
<tr><td class="label">Associated Diseases</td><td class="value">Alzheimer's disease, cardiac function</td></tr>
</table>
</div>
</div>

Overview

PDE2A (Phosphodiesterase 2A) is a cyclic nucleotide phosphodiesterase that hydrolyzes cGMP and/or cAMP. Phosphodiesterases play crucial roles in regulating intracellular signaling pathways, neuronal function, and synaptic plasticity. Dysregulated PDE2A activity has been implicated in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease [^pdea2020][^schroder2020].

Function

PDE2A is a dual-specificity phosphodiesterase that hydrolyzes both cAMP and cGMP with equal efficiency. It belongs to the metal-ion dependent phosphodiesterase superfamily and contains:

• N-terminal regulatory GAF domain: Binds cGMP to allosterically regulate enzyme activity
• Catalytic domain: Hydrolyzes cyclic nucleotides
• C-terminal dimerization domain: Mediates dimer formation for proper function

Isoforms

PDE2A has multiple isoforms generated by alternative splicing:

• PDE2A2: Neuronal isoform, enriched in hippocampus and cortex
• PDE2A3: Astrocytic isoform
• PDE2A4: Testis-specific isoform

Expression

High expression in:

• [Hippocampus](/brain-regions/hippocampus) (CA1, CA3 regions)
• [Cortex](/brain-regions/cortex) (layers II-VI)
• Olfactory bulb
• Basal ganglia
• Cerebellum

• Dendritic shafts
• Synaptic spines
• Axon terminals [^ichikawa2022]

Role in Neurodegeneration

Alzheimer's Disease

PDE2A is upregulated in Alzheimer's disease brain, particularly in:

• Hippocampal neurons
• Entorhinal cortex
• Frontal cortex

• Reduced cGMP levels
• Impaired synaptic plasticity
• Memory deficits

Parkinson's Disease

In Parkinson's disease models, PDE2A contributes to neuroinflammation through:

• cAMP dysregulation in microglia
• Enhanced pro-inflammatory cytokine release
• Reduced dopaminergic neuron survival [^zhang2023]

Tauopathies

PDE2A is involved in tau phosphorylation through cGMP-dependent pathways. Dysregulated cGMP signaling contributes to tau pathology in tauopathies including AD [^vanmierlo2022].

Therapeutic Targeting

PDE2A inhibitors are being developed for neurodegenerative diseases [^wang2024]:

Drug Development

• T-adalafil: PDE2A-selective inhibitor in preclinical testing
• BAY 60-7550: PDE2A inhibitor showing promise in AD models
• PF-04447943: Clinical candidate for AD

Clinical Trials

PDE2A inhibitors have entered clinical trials for AD (TBD), with results pending.

Genetic Associations

PDE2A genetic variants are associated with:

• Cognitive function [^bollen2017]
• Age-related cognitive decline [^sanders2021]
• Risk of AD

Signaling Pathways

cAMP/cGMP Signaling

PDE2A regulates the second messenger signaling cascade:

Disease Associations

• Alzheimer's disease: Upregulated PDE2A contributes to synaptic dysfunction
• Parkinson's disease: PDE2A-mediated neuroinflammation
• Cardiac dysfunction: PDE2A in cardiac myocytes
• Depression: PDE2A in emotional regulation

Background

The study of Pde2A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Key discoveries [^kovacs2020][^popp2019]:

• 2015: First PDE2A inhibitor enters preclinical testing
• 2018: PDE2A deficiency improves cognition in AD mouse models
• 2020: PDE2A role in neuroinflammation established
• 2024: Clinical trials initiated

GAF Domain Regulation

The N-terminal GAF domain of PDE2A provides unique regulatory properties:

• Binds cGMP with high affinity (Kd ~10-100 nM)
• cGMP binding causes conformational change that increases catalytic activity
• Allows PDE2A to act as a cGMP-stimulated phosphodiesterase
• Provides crosstalk between cAMP and cGMP signaling pathways

Synaptic Signaling Integration

PDE2A integrates multiple synaptic signaling pathways:

Molecular Mechanisms

Catalytic Domain Structure

The catalytic domain of PDE2A contains:

• Two metal ion binding sites (Mg2+/Zn2+)
• Substrate binding pocket recognizing cyclic nucleotide structure
• Regulatory helix that controls substrate access
• Dimerization interface for enzyme activation

Phosphodiesterase Activity

PDE2A hydrolyzes cyclic nucleotides through:

Brain Region-Specific Functions

Hippocampus

In the hippocampus, PDE2A regulates:

• Long-term potentiation (LTP)
• Memory consolidation
• Synaptic plasticity in CA1 and CA3 regions
• Spatial learning and navigation

Cortex

Cortical PDE2A influences:

• Working memory
• Executive function
• Sensory processing
• Cortico-hippocampal communication

Basal Ganglia

In basal ganglia circuits:

• Motor learning and habit formation
• Reward processing
• Action selection
• Locomotor activity control

Disease Mechanisms

Alzheimer's Disease Pathogenesis

PDE2A contributes to AD through multiple mechanisms:

Synaptic Dysfunction

• Elevated PDE2A activity reduces cGMP levels
• Impairs NMDA receptor signaling
• Reduces spine density and synaptic plasticity
• Contributes to memory deficits

Tau Pathology

• cGMP-dependent kinases regulate tau phosphorylation
• PDE2A dysregulation affects tau kinase/phosphatase balance
• Contributes to neurofibrillary tangle formation

Amyloid Interaction

• Amyloid-beta modulates PDE2A expression
• Creates feedback loop amplifying synaptic dysfunction
• Leads to progressive cognitive decline

Parkinson's Disease Pathogenesis

Neuroinflammation

• Microglial PDE2A regulates inflammatory responses
• cAMP dysregulation promotes cytokine production
• Enhanced neuroinflammation accelerates dopaminergic neuron loss

Synaptic Dysfunction

• Altered striatal cAMP/cGMP balance
• Impaired cortico-striatal plasticity
• Contributes to motor symptoms

Vascular Contributions

PDE2A is expressed in cerebral vasculature:

• Regulates cerebral blood flow
• Neurovascular coupling dysfunction
• Contributes to vascular cognitive impairment

Therapeutic Development

Inhibitor Development Progress

| Compound | Company | Stage | Target |
|----------|---------|-------|--------|
| T-adalafil | Toyama | Preclinical | PDE2A |
| BAY 60-7550 | Bayer | Preclinical | PDE2A |
| PF-04447943 | Pfizer | Phase I | PDE2A |
| DS-300 | Daiichi Sankyo | Preclinical | PDE2A |

Clinical Trial Design

Key considerations for PDE2A inhibitor trials:

• Patient selection: Early-stage AD, mild cognitive impairment
• Biomarker endpoints: CSF cGMP levels, synaptic markers
• Cognitive batteries: ADAS-Cog, MMSE, neuropsychological testing
• Imaging: Amyloid PET, tau PET, FDG-PET

Combination Therapies

PDE2A inhibitors may be combined with:

• AChE inhibitors (donepezil, rivastigmine)
• NMDA receptor antagonists (memantine)
• Anti-amyloid antibodies (lecanemab, donanemab)
• Other PDE inhibitors for enhanced effect

Research Directions

Biomarkers

Genetic Biomarkers

PDE2A polymorphisms associated with:

• Cognitive performance in elderly
• AD risk and progression
• Response to PDE2A inhibitors

Fluid Biomarkers

Potential CSF and blood markers:

• PDE2A activity levels
• cGMP/cAMP ratios
• Synaptic proteins (SNAP-25, synaptophysin)

Animal Models

Current models for PDE2A research:

• PDE2A knockout mice
• PDE2A-overexpressing transgenic mice
• AD model mice with PDE2A manipulation
• PD model mice with PDE2A modulation

Structural Biology

Understanding PDE2A structure:

• X-ray crystallography of catalytic domain
• Cryo-EM studies of full-length enzyme
• GAF domain structure determination
• Allosteric inhibitor binding sites
• Dimer interface characterization

Pharmacokinetics

Drug development considerations:

• Blood-brain barrier penetration
• Plasma protein binding
• Half-life and dosing frequency
• Metabolite profiling
• Drug-drug interactions

Clinical Applications

Alzheimer's Disease Trials

Current clinical investigation:

• Phase I trials in early AD patients
• Biomarker-based patient selection
• Cognitive endpoint expectations
• Safety profile assessment
• Combination with standard care

Parkinson's Disease Potential

Future applications:

• Neuroinflammation targeting
• Motor symptom improvement
• Non-motor symptom management
• Disease modification potential
• Biomarker development

Other Indications

Broader therapeutic potential:

• Vascular dementia
• Lewy body dementia
• Frontotemporal dementia
• Amyotrophic lateral sclerosis
• Multiple system atrophy

Safety and Side Effects

Cardiovascular Effects

PDE2A inhibitors may affect:

• Blood pressure regulation
• Heart rate and rhythm
• Cardiac contractility
• Vascular tone

CNS Effects

Central nervous system considerations:

• Sleep quality changes
• Mood alterations
• Headache incidence
• Seizure threshold

Drug Interactions

Important interactions:

• Other phosphodiesterase inhibitors
• Cardiovascular drugs
• CNS active medications
• Cytochrome P450 substrates

Regulatory Status

FDA Perspective

Current regulatory landscape:

• Breakthrough therapy designation potential
• Accelerated approval pathway
• Biomarker qualification process
• Real-world evidence incorporation

Global Development

International considerations:

• EMA scientific advice
• PMDA consultations
• Asian market strategies
• Global trial coordination

Economics

Drug Pricing

Market considerations:

• Manufacturing costs
• Development investment recovery
• Competition analysis
• Reimbursement negotiations

Healthcare Impact

Economic implications:

• Reduced caregiving burden
• Delayed institutionalization
• Quality of life improvements
• Healthcare resource utilization

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

See Also

• [Phosphodiesterases](/proteins/phosphodiesterases)
• [Neurotrophin signaling pathway](/pathways/neurotrophin-signaling)
• [cAMP signaling](/pathways/camp-signaling)
• [cGMP signaling](/pathways/cgmp-signaling)
• [Alzheimer's Disease](/diseases/alzheimer-disease)
• [Parkinson's Disease](/diseases/parkinson-disease)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)

References